Carrie S Oliphant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3476074/publications.pdf

Version: 2024-02-01

1163117 1125743 23 177 8 13 citations h-index g-index papers 23 23 23 393 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ivabradine: A Review of Labeled and Off-Label Uses. American Journal of Cardiovascular Drugs, 2016, 16, 337-347.	2.2	26
2	Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 148-154.	1.6	24
3	Consequences of treating false positive heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2015, 40, 512-514.	2.1	22
4	Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review. Clinical Cardiology, 2017, 40, 407-412.	1.8	17
5	Fever as a Risk Factor for Increased Response to Vitamin K Antagonists: A Review of the Evidence and Potential Mechanisms. Thrombosis Research, 2015, 135, 5-8.	1.7	16
6	Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Journal of Managed Care Pharmacy, 2014, 20, 187-193.	2.2	11
7	A review on cardiovascular effects of newer hypoglycaemic medications. Annals of Medicine, 2017, 49, 603-612.	3.8	10
8	Effects of propofol on vasopressor use in patients with sepsis and severe sepsis: A pilot study. Journal of Critical Care, 2016, 35, 155-160.	2.2	9
9	Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. American Journal of the Medical Sciences, 2016, 351, 309-316.	1.1	8
10	Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease. Current Vascular Pharmacology, 2010, 8, 93-101.	1.7	6
11	Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results. Journal of the American Board of Family Medicine, 2017, 30, 556-557.	1.5	6
12	Colchicine for the Treatment of Acute and Recurrent Pericarditis. Annals of Pharmacotherapy, 2014, 48, 1050-1054.	1.9	5
13	Acute Kidney Injury in Patients Continued on Renin-Angiotensin System Blockers During Hospitalization. American Journal of the Medical Sciences, 2017, 353, 172-177.	1.1	5
14	Novel oral anticoagulants for the prevention and treatment of thromboembolism. Future Cardiology, 2013, 9, 849-861.	1.2	3
15	The effect of obesity on the rate of heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2018, 29, 387-390.	1.0	3
16	Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review. Future Cardiology, 2014, 10, 229-233.	1.2	2
17	Impact of a Pharmacist on Compliance With Hospital Core Measures. Journal of Pharmacy Practice, 2014, 27, 379-383.	1.0	1
18	Key Articles and Guidelines in the Management of Patients Undergoing Cardiac Surgery. Journal of Pharmacy Practice, 2015, 28, 67-85.	1.0	1

#	Article	IF	CITATIONS
19	Edoxaban Use in Nonvalvular Atrial Fibrillation With Valvular Heart Diseaseâ€"Insights from <scp>ENGAGE AFâ€TIMI</scp> 48. Clinical Cardiology, 2017, 40, 612-613.	1.8	1
20	\hat{l}^2 -Blockade in Heart Failure With Reduced Ejection Fraction: Does Heart Rate Control Influence Readmissions?. Journal of Pharmacy Practice, 2018, 31, 40-45.	1.0	1
21	Pharmacists: An Important Resource to Improve Core Measure Performance. Hospital Topics, 2013, 91, 65-68.	0.5	O
22	Analysis of Antithrombotic Therapy after Cardioembolic Stroke Due to Atrial Fibrillation or Flutter. Hospital Pharmacy, 2013, 48, 127-133.	1.0	0
23	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. Future Cardiology, 2018, 14, 89-99.	1.2	0